TROPION-Lung01, a phase 3 randomized study, is evaluating Dato-DXD vs. docetaxel in previously treated EGFR-mutated locally advanced/metastatic NSCLC [60]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.